IDENTIFICATION AND CHARACTERIZATION OF CONTACT SITES BETWEEN HUMAN CHORIONIC GONADOTROPIN AND LUTEINIZING HORMONE/CHORIOGONADOTROPIN RECEPTOR by Jeoung, Myoungkun
University of Kentucky 
UKnowledge 
University of Kentucky Doctoral Dissertations Graduate School 
2003 
IDENTIFICATION AND CHARACTERIZATION OF CONTACT SITES 
BETWEEN HUMAN CHORIONIC GONADOTROPIN AND 
LUTEINIZING HORMONE/CHORIOGONADOTROPIN RECEPTOR 
Myoungkun Jeoung 
University of Kentucky, mkjeou0@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Jeoung, Myoungkun, "IDENTIFICATION AND CHARACTERIZATION OF CONTACT SITES BETWEEN HUMAN 
CHORIONIC GONADOTROPIN AND LUTEINIZING HORMONE/CHORIOGONADOTROPIN RECEPTOR" 
(2003). University of Kentucky Doctoral Dissertations. 264. 
https://uknowledge.uky.edu/gradschool_diss/264 
This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been 
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
  
 
 
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
 
 
 
 
 
 
Myoungkun Jeoung 
 
 
 
 
 
 
 
 
 
The Graduate School 
 
University of Kentucky 
 
2003 
  
 
 
 
 
 
 
 
 
IDENTIFICATION AND CHARACTERIZATION OF CONTACT SITES BETWEEN 
HUMAN CHORIONIC GONADOTROPIN AND LUTEINIZING 
HORMONE/CHORIOGONADOTROPIN RECEPTOR 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Arts and Sciences 
at the University of Kentucky 
 
 
By 
Myoungkun Jeoung 
 
Lexington, Kentucky 
 
Director:  Dr. Tae H. Ji, Professor of Chemistry 
 
Lexington, Kentucky  
 
2003 
 
Copyright © Myoungkun Jeoung 2003 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
IDENTIFICATION AND CHARACTERIZATION OF THE CONTACT SITES 
BETWEEN HUMAN CHORIONIC GONADOTROPIN AND LUTEINIZING 
HORMONE/CHORIOGONADOTROPIN RECEPTOR 
 
 
The luteinizing hormone receptor (LHR) belongs to the G protein-coupled receptor 
family.  It consists of two distinct domains; the N-terminal extracellular exodomain and the 
membrane associated endodomain which includes 7 transmembrane domains, 3 exoloops, 3 
cytoloops and a C-terminal tail.  Sequence alignment and computer modeling suggest the 
presence of Leu Rich Repeat (LRR) motifs in the exodomain.  Although their structural 
similarity is high, each LRR is not equally important for hormone binding.  Ala-scanning and 
truncation studies performed in our laboratory suggest that LRR2 and LRR4 appear to be the 
most crucial.  The Ala-scanning data suggest that Leu103 and Ile105 in LRR4 are important for 
hormone binding.  However, it is not clear whether these two residues make direct contact with 
human chorionic gonadotropin (hCG) or if they are necessary for the overall structural integrity 
of LRR4.  In this work, the LHR peptide mimics of LRR4 were used for photoaffinity labeling to 
determine whether Leu103 and Ile105 directly interact with hormone.  Furthermore, LRR4 
peptides containing the photoactivable benzoylphenylalanine (Bpa) were used to determine 
whether the LRR structure really exists in the LHR exodomain, whether LRR 4 interact with 
hCG, and which residues of LRR4 interact with hCG.  Bpa was directly incorporated into 
different positions of the LRR4 peptide sequence to examine the labeling ability of individual 
amino acids.  The results suggest that LRR4, in particular the sequence of Lys101-Cys106, 
makes direct contact with hCG.  However Leu103 and Ile105 do not interact with hCG but may 
form the hydrophobic core of the LRR4 loop, which appears to be crucial for the LRR structure.  
  
Existing data suggest that glycoprotein hormones initially bind the exodomain.  The 
hormone/exodomain complex undergoes conformational adjustments and stimulates the 
endodomain of the receptor to generate hormone signals.  The exoloops modulate hormone 
binding and signaling; however, little is known about whether the hormone/exodomain complex 
contacts the endodomain.  To address this issue, we investigated whether the exoloops interact 
with the hormone.  First, we examined exoloop 3 that connects transmembrane domains 6 and 7 
which are important for signal generation.  We present the first physical evidence that LHR 
exoloop 3 interacts with hCG. 
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Chapter One 
 
Introduction 
 
1.  Structure of Glycoprotein Hormones 
 Human chorionic gonadotropin (hCG) and luteinizing hormone (LH) belong to the 
glycoprotein hormone family, which also includes follicle stimulating hormone (FSH) and 
thyroid stimulating hormone (TSH).  They consist of two noncovalently associated protein 
subunits, a ~15 kD α-subunit and a ~23 kD β-subunit (1).  For each mammalian species, the 
common α subunits are encoded by a single gene and have the identical amino acid sequence (2).  
In contrast, the β subunits differ for each glycoprotein hormone and are encoded by distinct 
genes (2, 3).  The α-subunit consists of 92 amino acids as compared to 145 amino acids in the β-
subunit of hCG, the LH β-subunit has 121 amino acids.  The sequences of hCG β- and LH β-
subunits are similar except for 16 residues and the extra 24 amino acids at the hCG C-terminal 
region.  Both hormones have similar structure and bind to the same receptor (LH/CG receptor).  
In 1994, the crystal structure of deglycosylated hCG was reported (4) (Figure 1-1).  hCG 
subunits are tightly, non-covalently associated with each other.  Even with no sequence 
homology, both subunits share similar polypeptide folds.  The two individual subunits are 
stabilized by three intra-chain disulfides for each subunit (5).  Each chain is folded into 3 loops: 
αL1, αL2, and αL3 for the α-subunit and βL1, βL2 and βL3 for β-subunit.  In addition, a 
segment of the β-subunit wraps around the α-subunit.  This loop is formed by a Cys90-Cys110 
disulfide bond that is known as the seat belt region.  It plays an important role in receptor 
binding and maintaining the structural integrity of the heterodimer (4, 6, 7).  FSH also has this 
seat-belt loop structure (8).   
Both subunits of hCG are heavily glycosylated with two N-linked glycosylation sites on both the 
α-and β-subunits and four additional O-linked glycosylation sites on the β-subunit.  The 
carbohydrates on the hormone account for about 30-35% of the total mass of the hormone (9, 
10).  The carbohydrates on the hCG are not necessary for receptor binding.  Deglycosylated hCG 
treated with anhydrous hydrofluoric acid can bind to its receptor with slightly increased affinity.  
However, deglycosylated hCG can not induce the hormone signaling (11-13).  Only the dimer is 
capable of binding to receptors to induce biological responses (1), whereas the dissociated  
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Figure 1-1. Human chorionic gonadotropin (hCG) crystal structure 
Deglycosylated hCG has been crystallized.  hCG consists of α subunit (red) and β 
subunit (green).  Both subunits are folded into a three-loop-structure, tightly intertwined with 
each other.  A segment of the β subunit wraps around the α subunit like a seat belt (blue).
 3
subunits lose high affinity binding activity (14). 
 
2.  Biological Functions of Glycoprotein Hormones 
 FSH, LH and TSH are secreted from the anterior pituiatary gland.  While hCG is 
produced from multinuclear syncytiotrophoblast cells in the human placenta.  These hormones 
bind to their cognate receptors and generate signals into the target cells.  In general, the signaling 
involves the activation of adenylyl cyclase (AC) to produce cAMP (14) and phospholipase 
Cβ (PLCβ) to produce inositol trisphosphate (IP3) and diacylglycerol (DAG) (15).  LH and FSH 
stimulate ovarian and testicular functions by regulating gametogenesis and steroid hormone 
synthesis in the gonads.  TSH regulates the release of thyroid hormones (1). 
LH binds to the LH receptor (LHR) expressed in thecal and granulosa cells in the female 
ovary and Leydig cells in the male testis.  LH initiates steroidogenesis.  In the ovary, LH 
promotes the ovulation of fully developed Graffian follicles and luteinization (16, 17).   
FSH and FSHR play crucial roles in the gonad development and gamete production in 
both sexes.  FSHR is present in granulosa cells in the ovary and Sertoli cells in the testis (18).  
hCG stimulates progesterone production in the ovarian corpus luteum, which prevents the onset 
of the new ovulation cycle by stimulating the ovary to maintain the corpus luteum and by 
prolonging progesterone synthesis (17).  During pregnancy, relatively high amounts of hCG can 
be detected in urine and serum.  Elevated hCG in urine and serum is used for the pregnancy test.  
Intact hCG and hCG fragments have been detected in 25% of ovarian and 35% of testicular 
tumors (19, 20).  In urine and serum of tumor patients, the fragments of the β-subunit have been 
detected.  Based on these observations, hCG can be used for tumor detection in addition to the 
pregnancy test (18). 
 
3.  LH/CG Receptor Structure 
 The glycoprotein hormone receptors belong to the superfamily of G protein-coupled 
receptors (GPCRs) (21).  Nearly 2000 GPCRs have been cloned.  GPCRs consist of seven 
transmembrane domains (TM), an extracellular N-terminal segment, 3 extracellular loops 
(exoloops), 3 cytoplasmic loops (cytoloops), and a C-terminal tail (Figure 1-2) (22).  The 
identified ligands of GPCRs are proteins, peptides, neurotransmitters, biogenic amines, odorants, 
and photons (21).  There is relationship between the size of ligand and the length of exodomain  
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Figure 1-2. Structure of the gonadotropin receptors 
The LH/CG receptor consists of a ~350 amino-acid long extracellular domain (exodomain) and a 
membrane-associated domain (endodomain) of equal size.  The exodomain is thought to include 
8~9 Leu-rich repeats (LRRs), each consisting of a β strand (shown as arraw) and an α helix 
(shown as green cylinder).  A schematic model of the LRRs in the exodomain and the seven 
transmembrane domains in the endodomain is shown.  The endodomain consists of three 
exoloops, three cytoloops, seven transmembrane domains, and a C-terminal tail. 
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of its cognate receptor (23).  For example, the exodomain of adrenergic receptor is 11-30 amino 
acids.  The N-terminal halves of the glycoprotein hormone receptors are ~350 amino acids (21, 
23).  
 The LH receptor has a molecular weight of 75 kD and comprises 674 amino acid 
residues in human.  It consists of two equal halves, an extracellular N-terminal half (exodomain) 
and a membrane associated C-terminal half (endodomain) as shown in Fig 1-2 (24-28).  The 
~350 amino acid exodomain alone is capable of high affinity hormone binding (29-31),  although 
this binding can not generate hormone action (31, 32).  Receptor activation occurs in the 
endodomain which is similar in size to the entire molecule of many other GPCRs (21, 33).  The 
crystal structure of porcine ribonuclease inhibitor shows that there are 15 Leu-Rich-Repeats 
(Leu/Ile-X-Leu/Ile), and the ligand of pRI binds to β inner lining (34, 35) (Figure 1-3).  The 
glycoprotein hormone receptors have been modeled from the established Leu-Rich-Repeat 
(LRR) crystal structures, sequence alignment, and computer modeling (36-38).   In the LH 
receptor, the exodomain assumed to have 8-9 LRRs, and the inner lining presumably interacts 
with the hormone.  LRRs are 20-29-residue sequence motifs present in a number of proteins with 
diverse functions.  The primary function of these motifs appears to provide a versatile structural 
framework for protein–protein interactions.  Each LRR consists of a short β strand linked to an 
α helix in parallel to each other, and LRRs form a horseshoe-shaped structure with the inner 
lining of parallel β strands and the outer lining of α helices (Figure 1-3).  LRR is stabilized by 
hydrophobic interactions among residues, particularly involving Leu and Ile.  It has been 
suggested that hCG interacts with the inner side of the Leu-Rich Repeat structure (36) (Figure 1-
4).  The LRR domains, exon 2-8, of the LH, FSH, and TSH receptors share about forty three 
percent sequence similarities (22, 39).  However, the similarity diminishes at the  
N- and C-terminal portion of the exodomain with amino acids insertion in the FSH and TSH 
receptors, suggesting that these regions may be important for hormone specificity (40-43).  In the 
exodomain, LRRs  
are flanked by Cys-rich domains, which are thought to protect the first and last LRRs in the 
model (44).  Many existing data support the importance of the N-terminal region of the 
glycoprotein hormone receptor for hormone binding (40, 43, 45, 46) and cell surface expression 
(47, 48). 
The LHR exodomain has six consensus N-linked glycosylation sites with the consensus sequence  
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Figure 1-3.  Crystal structure of porcine ribonuclease inhibitor  
Porcine ribonuclease inhibitor (pRI) has been crystallized with its ligand.  pRI has 15 Leu-rich 
repeat (LRR) motifs.  Horseshoe conformation is formed from regular repeat units of β sheets 
(green) and α helical domains (red).  Ribonuclease A (blue) binding sites are the inner lining of 
β turns. 
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Figure 1-4.  Model for the interaction of the LH/CG receptor exodomain with hCG   
The concave, front side of hCG (α subunit: red, β subunit: green) is thought to interact with the 
inner lining of the 1/3 donut structure formed by LRRs of the exodomain (blue).  
hCG/exodomain complex is shown from the side (A) and from the top (B). 
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of Asn-xxx-Ser/Thr (6, 49, 50).  Enzymatic removal of the glycans from the exodomain did not 
affect the hormone binding, suggesting that they are important for targeting but not for hormone 
binding and receptor activation (6). 
Each of the seven transmemberane (TM) domains of LH receptor is generally composed 
of 20-27 amino acids.  The seven TMs of rhodopsin and adrenergic receptors are arranged as a 
closed loop in the counterclockwise direction from TM 1 to TM 7 when viewed from the 
extracellular surface (51) (Figure 1-5).  The intracellular C-terminal tail of the receptor contains 
phosphorylation sites by protein kinase C.  This region also contains several Ser and Thr residues 
that can be phosphorylated by protein kinase A.  Although the overall sequence homology is low 
among glycoprotein hormone receptors and other GPCR, the homology is high at the 
endodomains of the glycoprotein hormone receptors (22, 39).   
 
4.  Hormone - Receptor Interaction  
 Existing data suggest that glycoprotein hormones initially bind to the exodomain, 
and the resulting hormone/exodomain complex undergoes conformational adjustments (23) to 
make in secondary contacts with the endodomain (51) (Figure 1-6).  The secondary interaction is 
thought to be responsible for signal generation (6, 51, 52).  Although the crystal structure of 
deglycosylated hCG has been determined (4, 53) (Figure 1-1), the details are still unknown how 
the structurally similar glycoprotein hormones specifically interact with their cognate receptors.  
The high affinity hormone binding to the receptor is necessary for hormone signal induction.  
Glycoprotein hormones utilize the same effectors, adenylyl cyclase and phospholipase C β (15), 
(54), (55).  Therefore, it was speculated that the hormone specific β subunit would bind the 
exodomain, while the common α subunit would activate the endodomain to induce the common  
hormonal signals (56).   
 Several important contact sites of the receptor-binding domains within the hCG 
molecule are identified by hCG crystal structure and other studies using photoaffinity labeling, 
chemical modification, and mutational analyses.  Previous studies showed that the amino acids 
important for receptor binding are located at α 40-50 (57) and the C-terminal region (α88-92) 
(58-60) in the α-subunit, hydrophobic residues (β38-57), positive charged hydrophilic residues 
(β94-99), and the seatbelt region in the β-subunit (61-66) (Figure 1-1).  This has been supported 
by the observation that the exodomain makes direct contacts with both subunits of hCG (47, 67).   
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Figure 1-5.  Computer model of the LH/CG receptor endodomain  
The seven transmembrane helices, three exoloops (orange), and three cytoloops of the receptor 
endodomain are shown from the side (A), from the outside of the cell (B), and the arrangement 
of the transmembrane domains (1-7) as viewed from the outside of the cell (C).  Upon hormone 
binding, the movements of TM 3 (red) and 6 (blue) have been reported from rhodopsin, β2-
adrenergic receptor, and dopamine receptors. 
 10
 
 
 
 
 
Figure 1-6.  LH/CG receptor activation and signal transduction 
The receptor endodomain modulates hormone binding to the exodomain.  The 
hormone/exodomain/endodomain complex undergoes conformational adjustments which are 
responsible for activating the receptor and transducing the hormone signals.  Activated adenylyl 
cyclase produces cAMP.  Activated phospholipase Cβ generates IP3 and diacyl glycerol. They 
regulate protein kinase A activation, Ca2+ mobilization, and protein kinase C activation, 
respectively. 
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However, limited information is available regarding the precise hormone contact residues and 
sites in the exodomain.  Three peptide mimics of the exodomain, peptide21-38 (the N-terminal 
region), peptide102-115 (LRR 4), and peptide253-266 (hinge region) could inhibit 125I-hCG binding to 
membranes expressing the LH/CG receptor (40).  Several reports of mutagenesis within the 
exodomain, as well as chimeric and deletion studies have further localized the binding regions of 
the receptor.  A number of ionic amino acids in the exodomain are found to be important for 
hormone binding (68).  Cys residues in the N-terminal region are important for hormone binding 
(6).  Several distinct regions have been found to impact hormone binding from sequential 
truncation analysis (43).  They are near the boundaries of exons 1-2, exons 4-5, exons 5-6, and 
exons 9-10.  
 
5.  Modulation of Hormone Binding and Signaling by the Endodomain of Glycoprotein 
Hormone Receptor 
The exodomain alone is capable of high affinity hormone binding with almost 2 times 
higher affinity than the whole receptor (69).  The ~ 600 amino acid size of the hormone-
exodomain complex can not enter into the tight TM core, therefore, the exoloops are the 
reasonable contact sites for the interaction with hormone/exodomain complex since they are 
close to exodomain and can modulate the TM core.   
Exoloop1 is the longest of the three exoloops with 21 amino acids.  However, it has not  
been studied extensively.  Asp397 is conserved in all glycorprotein hormone receptors and is 
located at the junction of exoloop 1 and TM2, and the Asp397Asn mutation was found to abolish 
hormone binding (70).  It has not been proven whether exoloop 1 makes contact with the 
hormone/exodomain.  Exoloop 2 consists of 20 amino acids, it makes contact with the ligand in 
many GPCRs (71).  Ala substitutions for exoloop 2 residues of the LHR did not severely impair 
cAMP induction but reduced hormone binding affinity at Ser484, Asn485, Lys488 and Ser490 (69).  
Therefore, exoloop 2 is important for hormone binding, not for signal generation.  Recently, it 
has been reported that exoloop 2 and hinge region constrain fly LGR (Leu-rich repeat-containing 
G protein-coupled receptors) in inactive state (72).  Exoloop 3 is the shortest loop, consisting of 
11 amino acids, and connects TM6 and TM7.  It plays a crucial role in the generation of cAMP 
and IP signals.  All Ala substituted mutants bound hCG and induced cAMP except for Lys583.  
Lys583 is located in the junction of exoloop 3 and TM 7.  The Lys583Ala mutation significantly 
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increased hormone binding affinity.  Particularly, the Lys583Arg mutant has normal cell surface 
expression and hormone binding affinity, but the cAMP and IP signals were abolished.  This 
suggests that the hormone binding and receptor activation are separated (73, 74).   
 
6.  Receptor Activation and Signal Generation 
 The signal transduction in response to hormones is mediated by G protein-coupled 
receptors.  Activated GPCRs recruit intracellular heterotrimeric G proteins and stimulate 
GTP/GDP exchange to initiate receptor-specific signals.  Most of glycoprotein hormones utilize 
the same effectors, adenylyl cyclase to generate cAMP and phospholipase C β to produce 
inositol phosphates (IPs) and diacylglycerol (DAG) (15, 54, 55).  Gαs is responsible for the 
activation of adenylyl cyclase.  The Gβγ subunit is known to activate phospholipase C β  (75).  
The common seven TM helical structure in GPCRs is essential for signal transduction.  
Therefore, a common molecular mechanism has been suggested for activation of GPCRs.  A 
simple mechanism to transmit signal to the cytoplasmic surface is the modulation of 
transmembrane helices, which can cause structural change in the cytoplasmic domains of 
receptors (23).  There are several ways to accomplish this: rotation, piston, pulse, pivot and 
shuffle of TMs (23).  Upon receptor activation, the movements of TMs have been reported for 
different receptors showing different movements in different TMs; in TM3 and TM6 of 
rhodopsin, β2-adrenergic receptor, dopamine receptors, muscarinic receptors (76, 77), in TM2 
and TM7 of angiotensin II (AT1) receptor (78).  In both rhodopsin and the β2-adrenergic 
receptor, fluorescence spectroscopic studies show the movement of the TM helices.  Preventing 
TM3-TM6 movement blocks receptor-dependent G protein activation, implying that movement 
of these TM helices is critical for activation. 
 G protein-coupled receptors are maintained in an inactive conformation by intramolecular 
interactions.  The important conformational constraints maintain the receptor, preferentially, in 
an inactive conformation, and the constraints are released upon activation.  For example, 
cleavage of the thrombin receptor's amino-terminal exodomain at the Arg41-Ser42 peptide bond is 
necessary and sufficient for receptor activation (79).  When the exodomain was removed from 
TSHR, the basal level of cAMP was increased 4-7 fold without hormone binding (80).  From fly 
LGRs study, it is known that the exoloop 2 and hinge region constrain the receptor in an inactive 
state (81). 
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 Agonist-induced receptor dimerization is required for signal transduction for single TM 
receptors, such as growth factor receptors, which are thought to be activated by oligomerization 
(82, 83).  Several reports provide evidence that GPCRs can also form dimers (84-86).  However, 
different mechanisms of dimer formation were observed for different receptors suggesting that 
receptor oligomerization is not essential for G protein activation.  Some neurotransmitter 
receptors form a disulfide-linked dimer (87, 88).  There is evidence that the exodomain of one 
glycoprotein hormone receptor interacts with other receptor molecules to activate the 
endodomains of other receptors.  The coexpression of two different defective mutants receptor 
could rescue the hormone signaling. (89-91). 
 
7.  Photoaffinity Labeling and Affinity Cross-Linking 
 A number of techniques have been employed to identify the protein-protein contact sites.  
These techniques include X-ray crystallography, protein modification, affinity labeling, and 
photoaffinity labeling.  The first use of photogenerated reagents was introduced forty years ago 
(92).  Photoaffinity labeling has become a widely used tool to identify residues in the binding 
sites of biological macromolecules.  A photolabile reagent is attached to the macromolecule by a 
covalent bond. The photolysis of the complex generate a highly reactive species that labels 
chemical groups in the immediate environment (93) (Figure 1-7).  Photoaffinity labeling takes 
advantage of the principle that the affinity of the ligand for the receptor is the primary driving 
force of interaction.  Thus, this interaction would result in a site-specific modification of any 
amino acid in the vicinity of the binding domain on the receptor, as opposed to the chemical 
cross-linking, which is directed by the interacting amino acid for that particular reagent (94, 95).  
The general considerations for designing a photoaffinity label include the size of the photoactive 
group, its stability and reactivity, and the ease of synthesis.  Carbene, nitrene and free radical 
generating agents have been widely used in the study of proteins for identification, elucidation of 
the ligand binding domain, and study of function of the protein (95).   
 A heterobifunctional reagent contains two different reactive groups:  one photosensitive 
and the other conventional  N-hydroxysuccinimide (NHS) ester and imidate.  The general 
scheme of photoaffinity labeling is shown in figure 1-7.  Receptor peptides are derivatized with 
photoactivable reagents in the dark and radioactively labeled, and the peptide derivative is 
incubated with hCG to allow the specific interaction.  Since the binding is directed by the affinity 
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Figure 1-7.   General scheme of photoaffinity labeling  
Receptor peptides are derivatized with heterobifunctional photoactivable NHS-ABG, and then 
the radioactively labeled and derivatized peptides are incubated with hCG to allow the specific 
interaction.  After UV irradiation, the samples are separated on SDS-PAGE gel. 
 15
of the hCG for receptor peptide, the specificity of interaction is established in this step.  A short 
UV irradiation generates the reactive group on the photoreactive moiety.  The complex forms a 
covalent link with any amino acid approximately in the binding sites between hCG and receptor 
peptides.  The cross-linked complexes are slubilized and separated by SDS-polyacrylamide gel 
electrophoresis. 
 A benzophenone (Bp) unit is commonly employed for photoaffinity labeling (95).  It 
abstracts, irreversibly, hydrogen atom from available site (Figure 1-8).  Benzophenone has 
several advantages over other photoprobes: it is more reactive with C-H bonds than are others, 
also it is chemically more stable than other probes.  It has low reactivity toward water and other 
common solvents, and can be manipulated in ambient light and activated at long wave length 
(350-360 nm) UV which minimizes photolytic damage to proteins (95).  The amino acid analog 
4-benzoyl-L-phenylalanine (Bpa) has been used to study protein-protein interactions (96).  Since 
benzophenone substituted amino acids are stable under typical peptide synthesis conditions, Bpa 
can be directly incorporated at a defined position into the peptide sequence during solid-phase 
synthesis.  It makes it possible to the examination of individual amino acids for protein-protein 
interactions.  The advantages of Bpa as a photoprobe generally compensate the disadvantages 
resulting from the bulky and hydrophobic moiety (96, 97). 
 The photoaffinity technique has been used to study the interaction of glycoprotein 
hormones and their receptors for several years and have produced many data.  Our lab has 
synthesized a number of novel photosensitive, radioiodinatable and heterobifunctional reagents.  
We have established the macromolecular photoaffinity labeling technology (94, 98).  Our novel 
photoprobes have been used to identify hormone and receptor interactions.  In 1977, we used the 
cross-linking technique to identify the receptor on the cell surface.  Our photoaffinity labeling 
studies demonstrated the interaction of both hormone subunits to the receptor (99).  This was 
confirmed by independent studies of antibody binding, peptide binding, mutational analyses, 
chemical modification, and the hCG crystal structure (53, 57, 100-104).  We have studied where 
the contact sites are located on hormone to receptor (60, 105-107).  We also have examined 
where the contact sites are on the hormone, the exodomain, and endodomain of receptor (43, 47, 
67, 108-113). 
8.  Significance and Goals of Dissertation 
 hCG, LH and LHR play important roles in reproduction, women’s health, and some  
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Figure 1-8.  Structure and photochemistry of 4-benzoyl-L-phenylalanine (Bpa) 
(A) Bpa has an amino group and a carboxyl group, allowing for direct incorporation at a defined 
position into a peptide by solid-phase synthesis.  (B) Absorption of a photon at approximately 
350 nm results in the formation of a diradical (1).  The electrophilic oxygen interacts with weak 
C-H bonds (2), resulting in hydrogen abstraction.  The ketyl (3) and alkyl (4) radicals recombine 
to form a new C-C bond (5).  The diradical is only able to attack geometrically accessible C-H 
bonds. 
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cancers.  The hormone-receptor interactions generate signals and induce the hormone action.  
For example, antagonists can bind to receptors but can not induce hormonal responses (114, 
115).  Therefore, the ternary hormone-exodomain-endodomain complex should make the 
secondary conformational changes and adjustments to generate signals.  To understand the 
receptor activation mechanism, it is necessary to identify the amino acids responsible for the 
primary and secondary contacts. 
 hCG is important for maintaining pregnancy during the first trimester.  Insufficient 
amounts of hCG in the early pregnancy stage can cause miscarriage.  In addition, mutations on 
hCG and its receptor can impair the signal generation, resulting in infertility.  Approximately 6.7 
million couples in the United States suffer from infertility (116).  Analogs of the receptor and 
hormones could be used as therapeutics and diagnosis methods.  Current steroid contraceptives 
have serious side effects since steroids can affect most body cells.  Since gonadotropin receptors 
are found mainly in the reproductive organs, the drugs based on gonadotropins will have a higher 
specificity and fewer side effects.   
Therefore, it is essential to identify the contact points between hormone and receptor.  
hCG, but not its receptor, has been crystallized (4).  The receptor is difficult to crystallize due to 
its large flexible exodomain and transmembrane domains.  The secondary contact sites may be 
hard to find even from the crystal structure.  Understanding the hormone and receptor 
interactions will provide new insights in designing drugs and understanding the basic mechanism 
of GPCR activation.  Previously several regions important for hormone binding were mapped 
(43).  Ala-scanning and truncation studies on LHR suggest that some of the LRRs of the LH 
receptor are crucial for hormone binding.  In particular, LRR2 and LRR4 appear to be the most 
crucial (43, 117, 118).  These data also suggest that Leu103 and Ile105 in LRR4 are important for 
hormone binding (118).  However, it is not clear whether these two residues make contacts with 
LH/CG or if they are necessary for the overall structural integrity of LRR4.  Furthermore, LRR 
structure of LHR has been suggested from mutational analysis, sequence alignment and 
computer modeling.  There is no direct evidence for the existence of LRR structure in the LHR. 
 The goals of this dissertation work are to identify where the contact sides are on LRR4 
with hormone.  Some amino acids of exoloop 3 in the endodomain modulate the hormone 
binding to the exodomain.  It is necessary to examine whether exoloop 3 makes direct contacts 
with hCG.   
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 To accomplish these goals, I have utilized synthetic peptides, photoaffinity scanning, and 
binding assays to identify the contact sites between hCG and LH receptor. 
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Materials 
 
The N-hydroxysuccinimide (NHS) ester of 4-azidobenzoic acid (AB) was synthesized as 
described previously (119).  The N-hydroxysulfosuccinimide esters of ethylene 
glycolbis(sulfosuccinimidylsuccinate) (SES) were purchased from Pierce.  The hCG CR 127 and 
hCG subunits were supplied by the National Hormone and Pituitary Program.  Denatured hCG 
was prepared by boiling hCG in 8 M urea for 30 min.  Receptor peptides were synthesized and 
N-acetylated and C-amidated by Biosynthesis (Lewisville, TX).  They were purified on a Vydac 
C18 high performance liquid chromatography column using a solvent gradient from 100% of 
0.1% trifluoroacetic acid in water to 20% of 0.1% trifluoroacetic acid in water and 80% 1-
propanol.  The peptide mimics include the wild type receptor peptide corresponding to the LHR 
sequence of Asn96-Asp115 (LHR96-115), a mutant LHR96-115 with Leu103Ala and Ile105Ala mutations 
(LHR96-115(L103A/I105A)), a mutant LHR96-115 with the Lys101Ala mutation (LHR96-115(K101A)), a 
mutant LHR96-115 with the Lys112Ala mutation (LHR96-115(K112A)).  Bpa-containing LH/CG 
receptor peptides were synthesized, N-acetylated and C-amidated in >95% pure grade by 
Genemed Synthesis, Inc. (San Francisco, CA). 
 
Methods 
 
1.  Radioiodination of hCG or deglycosylated hCG 
1 mCi of Na125I in 10 µl of 0.1 M NaOH and 7 µl of chloramine T, initiating the reaction 
(1 mg/ml) in 0.1 M sodium phosphate (pH 7.5) were added to 5 µg hCG or deglycosylated hCG 
in 40 µl of 0.1 M sodium phosphate.  After 20 seconds, 7 µl of sodium metabisulfite (2.5 mg/ml) 
in 0.1 M sodium phosphate was added to terminate the iodination reaction.  Radioiodinated 125I-
hCG solution was mixed with 60 µl of 16% sucrose solution in 0.1 M sodium phosphate and 
fractionated on a Sephadex Superfine G-50 column (0.6 x 15 cm).  0.1% gelatin in 10 mM 
Na2HPO4 and 0.9% NaCl (pH 7.4) (PBS) was used to pre-equilibrate the column and elute the 
sample.   
 
2.  Derivatization and Radioiodination of Peptides 
NHS-ABG was freshly dissolved in dimethyl sulfoxide to a concentration of 50 mM, and 
then diluted with 0.1 M sodium phosphate (pH 7.5) to make a concentration of 20 mM NHS-
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ABG.  This reagent solution was immediately used to derivatize receptor peptides.  In the dark, 
10 µl of NHS-ABG was added to 30 µg of LHR receptor peptide in 40 µl of 0.1 M sodium 
phosphate (pH 7.5).  The mixture was incubated for 30 min for NHS-ABG at 25 °C.  The 
following were added to the derivatization mixture: 1 mCi of Na125I in 10 µl of 0.1 M NaOH and 
7 µl of chloramine T (1 mg/ml) in 10 mM Na2HPO4 and 0.9% NaCl (pH 7.4) (PBS).  After 20 s, 
7 µl of sodium metabisulfite (2.5 mg/ml) in PBS was introduced to terminate radioiodination.  
Derivatized and radioiodinated AB-125I-LHR96-115 solution was mixed with 60 µl of 16% sucrose 
solution in 0.1 M sodium phosphate buffer and fractionated on Sephadex Superfine G-10 column 
(0.6 x 15 cm) using PBS.  
 
3.  Affinity Cross-linking of 125I-LHR96-115 to hCG 
Disposable glass tubes were siliconized under dimethyldichlorosilane vapor overnight 
and autoclaved.  In each siliconized tube, 20 µl of PBS, hCG (70 ng in 10 µl PBS), and 125I-
LHR96-115 (100 ng in 10 µl of PBS) were mixed and incubated at 37 °C for 90 min.  After 
incubation, 3 µl of 0.1 mM of SES in DMSO was added to each tube and further incubated at 25 
°C for 20 min.  The cross-linking reaction was terminated by adding 3 µl of 5 mM Gly in PBS.  
The samples were boiled for 2 min in 2% SDS, 100 mM DTT, and 8 M urea.  The solubilized 
samples were electrophoresed on 8-12% polyacrylamide gradient gels.  Gels were dried on filter 
paper, and were exposed to PhosphorImager screens (Molecular Dynamics) overnight.  The 
imaging screen was scanned on a model 860 Storm Molecular Imager System (Molecular 
Dynamic), and radioactive band intensity was analyzed using ImageQuant software (Molecular 
Dynamics).  Gels were exposed to BioMax- x-ray film at –75 °C for ~4 days.  
 
4.  Photoaffinity Labeling of hCG 
The following solutions were sequentially introduced to siliconized glass tubes: 20 µl of 
PBS, 10 µl of hCG (10 ng/µl) in PBS, and 10 µl of ABG-125I-LHR96-115 (10 ng/µl) in PBS.  The 
mixtures were incubated at 37 °C for 90 min in the dark, irradiated with a Mineralight R-52 UV 
lamp for 90 s, and solubilized in 2% SDS, 100 mM dithiothreitol, and 8 M urea.  The samples 
were electrophoresed on 8-12% polyacrylamide gradient gels.  Gels were dried on filter paper 
and processed as described above.  
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5.  Competitive Inhibition of Affinity and Photoaffinity Labeling of hCG 
Competitive inhibition experiments were carried out as described for the affinity cross-
linking and photoaffinity labeling experiments, except that 10 µl instead of 20 µl of PBS was 
introduced to each tube, and the mixture was incubated with 10 µl of increasing concentrations 
of nonradioactive wild type or mutant LHR96-115 peptides in PBS  
 
6.  Inhibition of 125I-hCG binding to LHR 
A human embryonic kidney 293 cell line stably expressing human LHR was incubated 
with 100,000 cpm of 125I-hCG in the presence of increasing concentrations of nonradioactive 
wild type or mutant LHR96-115 peptides.  After several times washing the cells, the radioactivity 
associated with the cells was counted, and percent bound 125I-hCG was plotted against the 
nonradioactive receptor peptides.  The results were converted to Scatchard plot by plotting 
bound/free peptide versus bound peptide.  The plot was used to calculate the Ki value following 
the Scatchard equation. 
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Chapter Two 
 
hLHR peptide 96-115 labeling of hCG 
 
A.  Introduction 
The glycoprotein hormone receptors comprise two equal halves, an extracellular 
N-terminal half (exodomain) and a membrane associated C-terminal half (endodomain) as shown 
in Figure 1-2.  The exodomain of LHR alone is capable of binding hCG with high affinity (29-
31).  The sequence alignment shows a Leu Rich Repeat (LRR) motif (Leu/Ile-x-Leu/Ile) in the 
exodomain (24), (120) (Figure 1-4).  In the crystal structure of ribonuclease inhibitors, the LRRs 
assume the nonglobular horseshoe like structure in which an individual LRR forms a loop 
consisting of a β strand connected to parallel α helices.  The glycoprotein hormone receptors 
have been modeled based on these established LRR crystal structures, (36), (37), (121).  They 
show a one-third donut structure consisting of 8-9 LRRs and suggest that the inner lining 
interacts with the hormones (41).   
The previous results suggest that both flanking regions of the LRRs of LHR make contact 
with both subunits of hCG (43, 110, 112).  In particular, the region upstream of the LRRs has 
many contact sites with hCG.  Also, LRRs had been examined to see whether they exist and 
contact hCG.  Leu/Ile residues in the β strands of the LRRs were Ala-scanned because they are 
thought to form the inner lining of the 1/3 donut structure, which is supposed to contact hCG like 
porcine ribonuclease inhibitor.  The results showed that LRRs 2 and 4 are important for hormone 
binding since the substitutions for any of the Leu/Ile residues in the LRRs 2 and 4 resulted in the 
complete loss of hCG binding though the mutant receptors were expressed on the cell surface 
(117, 118).  Next, LRR2 was examined by Ala-scanning the amino acids from Val38 to Arg63.  
Several amino acids were found to be important:  Ile39 and Phe44 in the α helix and Ile53 and Ile55 
in the β strand and Ser59, Leu61 and Glu62 in the linker.  Subsequently, LRR4 was also Ala-
scanned.  Similarly, the Ala substitution for Leu103 and Ile105 in the β strand abolished hCG 
binding though the mutants receptors were expressed on the cell surface (118).  To characterize 
the side chain, Leu103 and Ile105 were individually substituted with a panel of different amino 
acids of hydrophobic, neutral, hydrophilic, or ionic nature.  The substitutions of Val, Phe, and 
Ile/Leu did not affect hCG binding although the Kd values were increased by 2-8 fold.  Deletion 
 23
and substitutions of other residues abolished hCG binding, although those mutants were 
expressed on the cell surface.  When Leu103 and Ile105 were switched with each other, the double 
mutant's Kd increased by 5 fold over the wild type Kd.  These data suggest that Leu103 and Ile105 
have unique functions.  Although mutational analysis is a powerful approach to screening 
potentially important contact sites of protein-protein interaction, this raises the question as to 
whether the LRRs directly interact with the hormone or indirectly influence the 
hormone/receptor interaction by affecting the global structure of the receptor exodomain due to 
mutation-induced conformational change. 
 
B.  Results 
Previously, it was tested whether LRR4 directly interacts with hCG using the peptide 
mimic of LRR4 spanning Asn96-Asp115 (111).  It was necessary to employ a tool that allows 
LRR4 peptide to bind tightly to the hormone.  To attain efficient cross-linking of LRR4 peptide 
into the hormone binding site, LHR96-115 was derivatized to produce 125I-AB-LHR96-115.  125I-AB-
LHR96-115 labeled both subunits with slightly higher labeling of the α subunit.  125I-AB-LHR96-115 
labeling of hCG is saturable depending on the UV irradiation time and concentration of 125I-AB-
LHR96-115 and hCG.  125I-AB-LHR96-115 does not label denatured hCG.  The derivatization of 
LHR96-115 did not affect LHR96-115 binding to hCG.  Furthermore, the derivatized peptide 
inhibited 125I-hCG binding to the LH receptor on intact cells.  Therefore, the labeling appears to 
be specific (111). 
The labeling could be blocked by underivatized wild type peptide but not by double 
mutant peptide with Leu103Ala and Ile105Ala substitutions (LHR96-115(L103A/I105A)). To determine 
the labeling site, we synthesized LHR96-115 analogs in which photoactivable 
benzoylphenylalanine (BPA) (96) replaced an amino acid at Lys101, Tyr102, Leu103, Ser104, Ile105 
and Cys106 positions (Figure 2-1).   
 
1.  Photoaffinity Labeling of 125I-Bpa102-LHR96-115 to hCG 
In a previous study, it was shown that the photoreactive group at K101 position of  
LHR96-115 specifically labeled hCG with specificity (111).  Therefore, the next amino acid of 
LHR96-115 of the β structure of LRR4 was replaced with Bpa.  125I-Bpa102-LHR96-115 was used to 
test whether Bpa analog peptide LHR96-115 would bind and label hCG with specificity.  125I- 
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Figure 2-1.   Model of LRR4, the structure of 4-benzoyl-L-phenylalanine (Bpa), and the 
sequence alignment of wild type and Bpa analog peptides  
(A) β structure is formed by Y102, L103, S104, I105 and C106.  (B) Bpa has an amino group and a 
carboxyl group, allowing for direct incorporation at a defined position into a peptide by solid-
phase synthesis.  (C) hLHR96-115 analog peptides have been synthesized by replacing one amino 
acid individually with Bpa at K101, Y102, L103, S104, I105 and C106 position. Bpa positions on 
LHR96-115 were marked with B.  The Leu-X-Ile motifs in LRR4 have been marked with gray box. 
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Bpa102-LHR96-115 was incubated with hCG and treated with UV.  The samples were solubilized in 
SDS under the reducing condition and electrophoresed, as described in “Materials and Methods”.  
The phosphoimage of the gel shows that 125I-Bpa102-LHR96-115 labeled both the α and β subunits 
of hCG (Figure 2-2,A).  The positions of hCG α and hCG β were determined by comparing the 
respective positions of 125I-hCG α and 125I-hCG β on the autoradiograph (Figure 2-2,A).  125I-
Bpa102-LHR 96-115 labeled hCG α 3 fold more than hCG β.  
 
2.  Labeling Specificity 
In order to determine the specificity of photoaffinity labeling, 125I-Bpa102-LHR96-115 was 
incubated with hCG and then irradiated with UV for different durations.  The labeling required 
UV irradiation and was dependent on the irradiation time, reaching the maximum labeling after 
60~90 s irradiation.  This UV dependence clearly indicates photoaffinity labeling.  In addition, 
the preferential labeling of hCG α was consistent, suggests the labeling specificity.  To further 
examine the specificity of photoaffinity labeling, the concentration of either hCG or the Bpa 
analog peptide was varied.  When a constant concentration of 125I-Bpa102-LHR96-115 was 
incubated with increasing concentration of hCG, the intensity of labeled hCG α and β bands 
gradually increased and showed saturation (Figure 2-2,B).  A similar result was observed when a 
constant amount of hCG was incubated with increasing concentrations of 125I-Bpa102-LHR96-115 
(Figure 2-2,C).  These results indicate that the photoaffinity labeling is dependent on both the 
Bpa analog peptide and hCG as the limiting factors.  In both cases, 125I- Bpa102-LHR96-115 labeled 
hCG α more than hCG β, an indication of labeling specificity.  Next, we examined the labeling 
specificity of 125I-Bpa102-LHR96-115.  One way to test the specific labeling is the displacement test 
using wild type peptide (LHR96-115) and a mutant peptide (LHR96-115(L103A/I105A)).  From previous 
data, the wild type peptide could bind to hCG with specificity, and also could inhibit the specific 
labeling of ABG-125I-LHR96-115.  However, the double mutant peptide (LHR96-115(L103A/I105A)) 
could not bind and label hCG(111).  To test whether the wild type and double mutant peptides 
could inhibit photoaffinity labeling of 125I-Bpa102-LHR96-115, hCG was incubated with 1µM 125I-
Bpa102-LHR96-115 in the presence of increasing concentrations of non-iodinated wild type peptide 
(Figure 2-3,A) and non-iodinated double mutant peptide (Figure 2-3,B).  Increasing 
concentrations of wild type peptide inhibited photoaffinity labeling in a dose-dependent manner, 
and the labeling was almost completely inhibited at 4 µM of non-iodinated LHR96-115 (Figure 2- 
 26
 
 
 
 
 
Figure 2-2.  Autoradiograph of photoaffinity labeled hCG subunits 
The peptide corresponding to the Bpa102 analog LHR96-115 sequence (Bpa102-LHR96-115) was 
synthesized and radioiodinated to produce 125I-Bpa102-LHR96-115. (A) A constant concentration of 
125I-Bpa102-LHR96-115 was incubated with a constant amount of hCG and irradiated with UV for 
increasing time periods.  The samples were solubilized in SDS under the reducing condition and 
electrophoresed as described in "Materials and Methods".  After electrophoresis, the gel was 
dried and autoradiographed using phosphoimager.  The percentage of the labeled hCG α and β 
subunit bands in each lane were calculated based on the total intensity of each lane, and 
presented in the bar graph.  (B) A constant concentration of 125I-Bpa102-LHR96-115 was incubated 
with increasing concentrations of hCG and irradiated with UV for 60 s.  (C) Increasing 
concentrations of 125I-Bpa102-LHR96-115 were incubated with a constant amount of hCG and 
irradiated with UV for 60 s. 
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Figure 2-3.  Specificity of photoaffinity labeling 
hCG was incubated with 1µM 125I-Bpa102-LHR96-115 in the presence of increasing concentrations 
of nonlabeled LHR96-115 (A), Bpa102-LHR96-115 (B), and double mutant peptide LHR96-
115(L103A/I105A) (C).  The samples were irradiated with UV for 60 s and processed as described in 
the legend of Figure 2-2. 
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3,A).  In contrast, the inhibition by LHR96-115(L103A/I105A) was significantly less effective, it could 
not compete out 125I-Bpa102-LHR96-115 labeling (Figure 2-3,B).  The results of the displacement 
test support the specificity of photoaffinity labeling of 125I-Bpa102-LHR96-115. 
 
3.  Biological Specificity of Photoaffinity Labeling 
 Next, I wanted to demonstrate the biological activity of 125I-Bpa102-LHR96-115.  It was 
checked by the photoaffinity labeling experiment with denatured hCG and the inhibition study 
on intact cells.  Denatured hCG lost its original conformation and could not bind to LHR 
expressed on the cell surface (111).  To test whether 125I-Bpa102-LHR96-115 could label denatured 
hCG, the increasing concentrations of 125I-Bpa102-LHR96-115 were incubated with a constant 
amount of denatured hCG and treated with UV (Figure 2-4,A).  125I-Bpa102-LHR96-115 did not 
label the biologically inactive denatured hCG even at the highest concentration.  If the Bpa 
peptide analog has a similar or the same structure as the native region of hCG and the 
corresponding region is involved in receptor binding, Bpa102-LHR96-115 could inhibit 125I-hCG 
binding to receptor on the cell surface.  The iodination of hCG did not affect hormone binding to 
receptors (111).  125I-hCG was incubated with 293 cells stably expressing wt LHR in the 
presence of increasing concentrations of the wild type LHR96-115 or Bpa102-LHR96-115 (Figure 2-
4,B).  The wild type LHR 96-115 inhibited 125I-hCG binding to the receptor with an inhibition 
constant (Ki) value of 30 µM, suggesting its binding to the receptor with a reasonable affinity for 
the peptide (40, 110).  Similary, the Ki value of Bpa102-LHR 96-115 was 38 µM.  These results 
show that the structures of LHR96-115 and Bpa102-LHR96-115 were similar enough to inhibit hCG 
binding to receptor on cell surface with similar Kis 
 
4.  Photoaffinity Scanning of β Strand of LRR4 
To determine the labeling residues in LRR 4, individual amino acids on LHR96-115 were 
substituted with photoreactive Bpa (Figure 2-1).  The Bpa peptides were tested in the same 
manner as Bpa102-LHR96-115 to determine which Bpa peptides label hCG effectively.  Some Bpa 
peptides could label hCG more efficiently than others (Figure 2-5).  These results indicate that 
the photoaffinity labeling is dependent on the Bpa position.  The peptides with Bpa at the Lys101, 
Tyr102, Ser104 and Cys106 position, labeled hCG efficiently, and their labeling was saturable 
depending on the UV irradiation time and the concentrations of 125I-Bpa peptides and hCG.   
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Figure 2-4.  Photoaffinity labeling of denatured hCG and inhibition of 125I-hCG binding to 
the receptor by LHR96-115 
(A) A constant amount of denatured hCG was incubated with increasing concentrations of 125I-
Bpa102-LHR96-115 and irradiated with UV for 60 s.  The samples were processed as described in 
the legend of Figure 2-2.  (B) 125I-hCG and intact 293 cells expressing LHR were incubated with 
increasing concentrations of unlabeled hCG, LHR95-115, Bpa102-LHR96-115, and LHR96-
115(L103A/I105A) peptides separately.  The results were plotted against the concentration of unlabeled 
hormone and peptides.   
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Figure 2-5.  Photoaffinity labeling of hCG with 125I-Bpa-LHR96-115 peptides  
Bpa-LHR96-115 analog peptides were synthesized with a substitution of Bpa at K101, Y102, L103, 
S104, I105, and C106.  100 nM hCG was incubated with 1 µM 125I-Bpa-LHR96-115 and irradiated 
with UV for 60s.  The samples were processed as described in the legend of Figure 2-2. 
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These Bpa peptides could not label denatured hCG.  To test whether Bpa substitution impacted 
the Bpa peptide structure, the displacement tests were performed by incubation of hCG and 125I-
Bpa102-LHR96-115 in the presence of increasing concentrations of other Bpa-LHR96-115 peptides.  
The data are shown in Figure 2-6.  125I-Bpa102-LHR96-115 labeling was inhibited by other 
nonradiolabeled Bpa-LHR96-115 peptides with Ki values of 1.8, 1.0, 1.4, 0.7, 0.9 and 1.1 µM for 
Bpa101, Bpa102, Bpa103, Bpa104, Bpa105, and Bpa106, respectively.  Furthermore, 125I-Bpa102-LHR96-
115 labeling of hCG was blocked by wild type peptide but not by double substituted LHR96-
115(L103A/I105A) peptide.  Bpa104-LHR96-115 peptide had Bpa in the middle of the β strand and 
showed the lowest Ki value of 0.7 µM.  The results suggest that the structures of Bpa analog 
peptides are similar to each other and can compete with wild type LHR96-115 peptide for hormone 
binding.  Also, the biological significance of these Bpa analog peptides was tested by inhibition 
of 125I-hCG binding to intact cells cells (Figure 2-7).  The Ki values are reasonable, as peptide 
concentration ranged from 35.3 to 50 µM.  Bpa104-LHR96-115 showed the lowest Ki.  This is 
consistent with the result in Figure 2-6.  This means Bpa104-LHR96-115 could inhibit 125I-hCG 
binding to receptor on cell surface the most efficiently among Bpa-LHR96-115 peptides.  Bpa102-
LHR96-115 labeled with the highest percentage at labeling hCG 58% of the time, but Bpa104-
LHR96-115 inhibited 125I-hCG binding to receptor the most efficiently.  In contrast, Bpa103-LHR96-
115 and Bpa105-LHR96-115 could not label hCG efficiently, but they could inhibit 125I-hCG binding 
to receptor on cell surface with Ki values of 44.3 and 43.3 µM respectively.  These results 
indicate that the photoaffinity labeling is dependent on the position of the Bpa group, but Bpa 
substitutions in LHR96-115 did not affect the Bpa-LHR96-115 binding to hCG (Figure 2-7).  These 
results suggest that Lys101, Tyr102, Ser104 and Cys106 face hCG, whereas Leu103 and Ile105 do not, 
consistent with the model in Figure 2-1.  Furthermore, the results are consistent with the view 
that Ser104, in the center of the β strand inner lining, is most effective in inhibition of 125I-hCG 
binding to receptors on cell surface.  In contrast, Leu103 and Ile105 appear to form the 
hydrophobic core of the LRR4 loop and to be crucial for the LRR structure.  The Ki values of 
inhibition by the Bpa analog LHR96-115 peptides were similar to each other: 50, 38, 44.3, 35.3, 
43.3 and 36.5 µM for LHR96-115 with Bpa101, Bpa102, Bpa103, Bpa104,  
Bpa105 and Bpa106, respectively.  This suggests that Bpa substitutions were tolerable, and their Ki 
values are reasonable as peptides.  However, the labeling is dependent on the Bpa position. 
5.  Photoaffinity Scanning on Proximal Region of β Strand of LRR4 
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Figure 2-6.  Inhibition of 125I-Bpa102-LHR96-115 photoaffinity labeling 
(A)  hCG was incubated with 1µM 125I-Bpa102-LHR96-115 in the presence of increasing 
concentrations of nonlabeled LHR96-115, LHR96-115(L103A/I105A), and Bpa-LHR96-115 peptides.  The 
samples were irradiated with UV for 60 s and processed as described in the legend of Figure 2-2.  
(B) The inhibition constants (Ki) were calculated. 
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Figure 2-7.  Inhibition of 125I-hCG binding to the receptor by Bpa-LHR96-115 peptides 
125I-hCG was incubated with intact 293 cells expressing LHR in the presence of 
increasing concentrations of unlabeled Bpa-LHR96-115 analog peptides with Bpa at K101, Y102, 
L103, S104, I105, and C106 positions as described in "Materials and Methods".  The results were 
plotted against the concentration of unlabeled peptides.  The inhibition constants (Ki) were 
calculated by scatchard plot.
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The β structure in the LHR96-115 seems to consist of Ser104 in the middle and Leu103 and Ile105 
facing the inside of the loop structure (Figure 2-1).  To confirm this β structure in LHR96-115, 
more Bpa analog peptides in LHR96-115 were synthesized and used for photoaffinity scanning.  
The locations of Bpa substitution were Asn96, Leu97, Arg99, Asn107, Thr108, Gly109, Ile110 and 
Asp115.  Proline was not substituted since many Proline residues are important for protein 
structures.  Lys112 was not substituted either since it was already tested (111).  These Bpa 
peptides were subjected to photoaffinity labeling, inhibition study with wild type LHR96-115 
peptide, and 125I-hCG binding to receptor on cell surface.  The percentages of photoaffinity 
labeling data are shown in Figure 2-8 and the inhibition of 125I-hCG binding data in Figure 2-9, 
A-C.  Although the percentages of labeling of Bpa analog peptides were diminished when Bpa 
was located away from β structure, the Ki values of Bpa analog peptides at Leu97, Arg99, Asn107, 
Thr108, Gly109, Ile110 and Asp115 were similar to each other, except for Asn96, and to those of 
previous Bpa analog peptides at Lys101, Tyr102, Ser104 and Cys106.  This result suggests that most 
of the Bpa analog peptides at LHR96-115 have a similar structure, and are competing with each 
other for the same binding site on hCG.  However, none of the Bpa analog peptides at Asn96, 
Leu97, Arg99, Asn107, Thr108, Gly109, Ile110 and Asp115 could label hCG more efficiently than at 
those of Lys101, Tyr102, Ser104 and Cys106.  These results suggest that the photoaffinity labeling is 
dependent on the position of the Bpa group.  When A Bpa was closer to the putative β strand 
could label hCG much more efficiently than a Bpa at a positon distant from the β strand. 
 
6.  The Displacement Test with the Peptides from Other Regions of the Exodomain and the 
Endodomain of LHR 
The existing data suggest multiple contact sites for the hCG/receptor interaction.  Several regions 
have been found by our group.  They are the N-terminal region (43, 110), Leu Rich Repeat 4 
(111, 118), and the hinge region (112).  In addition, exoloop 2 is involved in the interaction of 
the exodomain and endodomain (72, 112).  To extend the study on the relationship between the 
exodomain and the endodomain, hCG was photoaffinity labeled with 1 µM 125I- 
Bpa102-LHRexo3 in the presence of increasing concentrations of nonraidoactive N-terminal 
peptide (LHR17-36), Leu Rich Repeat 4 peptide (LHR96-115), the hinge region peptide (LHR246-
269), or the exoloop peptides (LHRexo1, LHRexo2 and LHRexo3).  Nonradiolabeled  
LHR96-115 and LHRexo2 blocked the labeling (Figure 2-10, A), but the inhibition by LHRexo1 was  
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Figure 2-8.  Photoaffinity labeling of hCG with 125I-Bpa-LHR96-115 peptides 
More Bpa-LHR96-115 analog peptides were synthesized with Bpa at Asn96, Leu97, Arg99, Asn107, 
Thr108, Gly109, Ile110 and Asp115 positions.  100 nM hCG was incubated with 1 µM 125I-Bpa-
LHR96-115 and irradiated with UV 60 s.  The samples were solubilized in SDS under the reducing 
condition and electrophoresed.  After electrophoresis, the gel was dried and autoradiographed 
using phosphoimager.  The data has been analyzed as described in the legend of Figure 2-2. 
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Figure 2-9.  Inhibition of 125I-hCG binding to the receptor by Bpa-LHR96-115 peptides 
125I-hCG was incubated with intact 293 cells expressing LHR in the presence of increasing 
concentrations of unlabeled Bpa-LHR96-115 peptides: (A) N-terminal, (B) β strand, and (C) C-
terminal regions of LHR96-115.  The results were plotted against the concentration of unlabeled 
peptides.  The inhibition constants (KI) were calculated by scatchard plot. 
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Figure 2-10.  Inhibition of 125I-Bpa102-LHR96-115 photoaffinity labeling with different region 
LHR peptides                                                                
(A)  hCG was incubated with 1µM 125I-Bpa102-LHR96-115 in the presence of increasing 
concentrations of nonlabeled N-terminal (LHR17-36), LRR4 (LHR96-115), hinge region (LHR246-
269), exoloop 1 (LHRexo1),  exoloop 2 (LHRexo2),  and exoloop 3 (LHRexo3) peptides.  The samples 
were irradiated with UV for 60 s and  processed as described in the legend of Figure 2-2.  (B) 
Schematic model for interaction of hCG and the LHR exodomain.  (C) 3D model of the LHR 
endodomain. 
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considerably weaker.  These results suggest the binding sites of LHR96-115 and LHRexo2 are close 
enough to compete with each other.  This gives an idea as to how hCG and the exodomain 
contact with each other (Figure 2-10, B) and also how the hCG/exodomain complex makes 
contact the endodomain, which is likely to be the exoloops (Figure 2-10, C).   
 
C.  Discussion 
Our observations on the exodomain and hCG suggest, for the first time, the existence of 
functional LRRs, particularly LRR 4, in the LHR exodomain. The β strand of LRR4 consists of 
Tyr102, Leu103, Ser104, Ile105 and Cys106 (Figure 2-1).  125I-Bpa-LHR96-115 with Bpa at the side of 
Lys101, Tyr102, Ser104 and Cys106 could label hCG much more efficiently than those with Bpa at 
the Leu103 and Ile105 position.  This result suggests that hCG binds at the side of Lys101, Tyr102, 
Ser104 and Cys106.  In contrast, Leu103 and Ile105 could not label hCG efficiently suggesting that 
Leu/Ile-X-Leu/Ile motives appear to be crucial for forming the hydrophobic core of the LRR 
loops and providing the structural framework of the1/3 donut structure.  They do not face and 
interact with hCG.  The labeling of Bpa peptides at Lys101, Tyr102, Ser104 and Cys106 are saturable 
and dependent on the hCG concentration, 125I-Bpa-LHR96-115 concentration, and UV irradiation 
time.  125I-Bpa-LHR96-115 peptides label bioactive hCG but not denatured hCG.  The 
photoaffinity labeling of 125I-Bpa-LHR96-115 blocked by non-iodinated wild type LHR96-115 but 
not by double-substituted mutant LHR96-115(L103A/I105A).  Both α and β subunits are labeled, the α 
subunit preferentially, suggesting that photoreactive Bpa can reach both.  This is possible since 
two subunits are closely entangled in its crystal structure (53, 104) (Figure 1-1).  Considering the 
length of Bpa, the physical proximity of Bpa and hCG α could be less than 5 Å.  Although the 
length of Bpa is quite similar to those of long side chain amino acids like Lys or Arg, the 
possible interference of the photoactivable Bpa group on binding of 125I-Bpa-LHR96-115 to hCG 
tested by affinity cross-linking experiments with wild type 125I-LHR96-115 with SES (Ethylene 
glycolbis-[sulfosuccinimidylsuccinate]) (111).  The data from affinity-cross-linking by SES and 
photoaffinity labeling by Bpa are similar, suggesting that the Bpa substitution does not affect the 
peptide structure and interfere with hCG binding and the subsequent labeling.  Furthermore, the 
biological significance of Bpa-LHR96-115 has been shown by the fact that Bpa-LHR96-115 peptides 
could inhibit 125I-hCG binding  
to receptor on intact cell surface with similar Ki values to wild type LHR96-115.  Although the Ki 
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values of peptides with Bpa at Leu97, Arg99, Asn107, Thr108, Gly109, Ile110 and Asp115 are similar to 
each other and to those of previous Bpa analog peptides at Lys101, Tyr102, Ser104 and Cys106, the 
labeling percentages of Bpa peptides at Asn96, Leu97, Arg99, Asn107, Thr108, Gly109, Ile110 and 
Asp115 were diminished when Bpa was located away from the putative β structure.  When the 
percentages of labeling are compared between at the N-terminus and C-terminus of LHR96-115 
peptide, Bpa from the C-terminus of LHR96-115 could label hCG more than from the N-terminus 
of LHR96-115.  From previous studies (43, 112), the N-terminus (LHR17-36) and the hinge (LHR246-
269) regions can label N-terminus of hCG, the exodomain would wrap around hCG and LRR4 can 
bind to the concave side of hCG, and the N-terminal region of LHR96-115 is closer to hCG than 
the C-terminal region of LHR96-115 (Figure 2-10,B).   
The glycoprotein hormones share the common α subunit and common effectors.  It is 
logical to speculate that the α subunit interacts with the endodomain and activates it since 
hormone activation is taken place in the endodomain.  The contact sites between the glycoprotein 
hormones and their cognate receptors are likely the exoloops, which could modulate 
transmembrane helices which causes an allosteric structural change in the cytoplasmic domains.  
This gives an idea how hCG and the exodomain might contact each other (Figure 2-11).  These 
multiple contact sites likely work synergistically to provide high affinity between hCG and its 
cognate receptor. 
The crystal structure of hCG has facilitated the investigations to localize the potential receptor-
binding regions (104).  The important regions are αL2 (40-50), α C-terminus (88-92), βL2 (38-
57) and the β seatbelt region (94-99).  However, the glycoprotein hormone receptors have not 
been crystallized probably due to the flexible N-terminal region, the glycans, their exodomain 
size which is similar to other whole GPCRs (21), and their membrane associated region.  The 
exodomain of glycoprotein hormone receptors has been modeled based on the sequence 
alignment, porcine ribonuclease inhibitor’s crystal structure, and homology modeling (36, 122).  
There are eight to nine LRRs providing the primary contact site for the cognate ligands.  The β 
sheet inner lining is thought to be the ligand contact site (36, 56, 123), perhaps interacting with 
the putative receptor binding C terminus and seat belt of hCG (4).  The importance of LRRs for 
hormone binding was proved by the deletion study (124).  LRR 1-6 are involved in hormone 
binding in LHR.  However, there is little experimental evidence for the hCG and receptor contact 
sites.  Recently, several reports described the LRR structure of LHR and the direct interaction of  
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Figure 2-11.  Model of the hCG, exodomain and endodomain of LH receptor  
Deglycosylated hCG has been crystalized.  hCG consits of α subunit (red) and β subunit (green).  
Two subunits are intertwined with each other.  Exodomain (blue) of LHR has the Leu-rich-repeat 
motifs (LRR)s.  Endodomain was modeled based on the rhodopsin transmembrane domain 
(gray).  It has three extracellular loops (orange), three cytoloops, 7 transmembrane domain, and a 
C-terminal tail. 
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the LRR4 β structure with hCG (111, 117, 118).  The imperfect LRRs are flanked by the short 
N- and C-terminal hinge regions.  These two flanking regions do not have homology among the 
glycoprotein hormone receptors; they are ascribed to the hormone specificity (43) and /or 
protecting the LRR structure (48).  It has been reported that the N-terminal region is important 
for receptor surface expression (48) and hormone binding (43, 124).  The C-terminal (hinge) 
region of the exodomain is important for receptor constraining in hTHSR (81) and also makes a 
contact with the hormone after the release of the receptor constraining (112).   
This work has been confirmed that the LRR structure exists in the exodomain of LHR 
and also proves that the LRR4 contacts with hCG at Lys101, Tyr102, Ser104 and Cys106 side of the 
β structure.  The information on exodomain/endodomain interaction could provide a general 
mechanism for the mutual modulation of the two distinct exodomain and endodomain and signal 
generation on GPCR.
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Chapter Three 
 
hLHR peptide labeling of exoloop 3 
 
A.  Introduction 
The gonadotropin and other glycoprotein hormone (FSH, hCG, LH and TSH) receptors 
consist of a ~350 amino acid long N-terminal extracellular exodomain and a C-terminal 
membrane associated endodomain of similar size (24, 25, 28).  Glycoprotein hormones initially 
bind to the exodomain, and the resulting hormone/exodomain complex modulates the 
endodomain (23).  The ternary interactions among the hormone, exodomain, and endodomain are 
crucial for activation of adenylyl cyclase to generate cAMP and phospholipase C β to produce 
inositol phosphate and diacylglycerol (6, 23, 51) (Figure 1-6). 
Despite the crucial roles of the ternary interactions, their character has not been well 
defined.  Only recently, some information has become available.  For instance, the exodomain of 
the TSH receptor appears to hold the endodomain in the inactive state (80).  In the case of the LH 
receptor, the hinge region (72, 81, 112) and Leu Rich Repeat 4 (LRR4) (111) of the exodomain 
interact with the endodomain.  Interestingly, the hinge residues are involved in pairing with 
exoloop 2 and suppressing the receptor activation (72, 81, 112).  In contrast, the LRR 4 residues 
appear to promote the activation of the endodomain (111), but the contact site is unknown.  
Conversely, some residues of exoloops 2 and 3 in the endodomain modulate the hormone 
binding to the exodomain (69, 125).  These observations suggest that the three exoloops are 
likely involved in interactions between the exodomain and endodomain.  However, the 
information on the function and structure of the exoloops is limited, and in particular, little is 
known about whether the hormone/exodomain complex contacts the exoloops. 
To address this issue, we set out to investigate whether exoloops indeed interact with the 
hormone.  As a first step towards this goal, we examined the shortest of the three exoloops in the 
endodomain, exoloop 3 of LHR and FSHR.  Exoloop 3 consists of 11 amino acids, connects 
transmembrane domains 6 and 7 that are important for activation of adenylyl cyclase (126, 127), 
and has been implicated in cAMP signal generation (109, 125).  
These results suggested the involvement of exoloop 3 in hormone binding, and raised a 
crucial question of whether exoloop 3 contacts the hormones.  However, the results raise the 
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question whether or not the observed effect of mutagenesis is caused directly by the mutated 
amino acid or indirectly by conformational changes in exoloop 3 due to mutation-induced 
folding changes.  One way to test its direct interaction is to use a synthetic peptide covering the 
mutated sequence. 
 
B.  Results 
1.  Exoloop 3 plays crucial and differential roles in cAMP and IP induction. 
Exoloop 3 is the shortest of the three exoloops, consisting of 11 amino acids, and one of 
the shortest exoloops found in G protein coupled receptors (51).  It is barely long enough to 
connect two TMs, 6 and 7, which have been implicated in signal transduction of LHR (6, 128).  
A slight change in exoloop 3 could modulate the two TMs allosterically.  LHR exoloop 3 is 
known to constrain the hormone binding at the exodomain but does not play a crucial role in 
cAMP induction except Lys583 (109).  However, little is known about the mechanisms or its role 
in IP induction.  To address this question, individual Ala substitutions of the exoloop 3 residues 
were stably expressed on HEK 293 cells and assayed for inositol phosphates IP1, IP2, IP3 and 
IPt (129) (Figure 3-1).   Most of the mutant receptors were incapable of inducing any of the IP 
species.  However, the Val574Ala and Ser582Ala mutants responded to hCG and induced IP.  
Since most of the mutants were incapable of inducing the IP species, we wondered whether the 
non-responding mutant receptors were expressed on the cell surface.  Therefore, the cells stably 
expressing with the mutants were assayed for hormone binding as well as hormone-dependent 
cAMP production.  All of the mutants bound hCG and all except LHRK583A induced cAMP, 
supported by the previous report (125).  The Ala substitutions differentially impacted hormone 
binding, cAMP induction, and IP induction.  IP induction was most sensitive to the Ala 
substitutions, whereas hormone binding was least sensitive.  Furthermore, the substituted 
residues impacting the three functions were diverse, suggesting distinct mechanisms and residues 
involved in each of the three functions.  For IP induction, all residues except Val574 and Ser582 
appear to be crucial, whereas Lys583 and perhaps a few others are essential for cAMP induction 
(129).    The results clearly show the differential mechanisms for cAMP and IP induction and the 
role of exoloop 3 in activation of adenylyl cyclase and PLC β.   
 
2.  Photoaffinity labeling of hCG with exoloop 3 peptide mimic 
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Figure 3-1. Differential effects of Ala substitutions on hormone binding, cAMP and IP 
induction 
To easily compare the Ala substitution effects on mutant receptors, hormone binding, cAMP and 
IP induction, the ratios of Kdwild type/Kdmutant (Kdwt/mut), maximum cAMP level of mutant/wild 
type (cAMPmut/wt) and maximum IPt level of mutant (IPmut/wt) were displayed.  Values over 1 
reflect that mutants are better than wild type. 
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In an attempt to test whether the LHR exoloop 3 interacts with hCG, the exoloop 3 peptide 
mimic, LHRexo3, was synthesized and used for affinity labeling of hCG.  The peptide was 
derivatized with a photoactivable reagent, the N-hydroxysuccinimide of 4-azidobenzoyl glycine 
(ABG), and radio-iodinated to produce ABG-125I-LHRexo3.  A constant amount of ABG-125I-
LHRexo3 was incubated with increasing concentrations of hCG and irradiated with UV.  Samples 
were solubilized in SDS under the reducing condition and electrophoresed.  The 
autoradiographic phosphoimage of the gel (Figure 3-2,A) revealed the labeling of the hCG α and 
β bands with the α band labeled slightly more than the β band.  The labeling increased in parallel 
to the concentration of hCG and then reached a plateau.  The result suggests that the labeling was 
saturable at a certain hCG concentration and that additional hCG was not labeled.  Furthermore, 
the maximum labeling was reached at 50 nM hCG for both of the hormone subunits, indicating 
that the slightly different labeling efficiencies of the subunits were independent of the hormone 
concentration.  Next, increasing concentrations of ABG-125I-LHRexo3 were incubated with a 
constant amount of hCG, photolyzed, and processed as before.  The resulting autoradiograph 
shows the labeling of both hCG α and β subunits, and shows a labeling plateau (Figure 3-2,B).  
In the next experiment, a constant amount of ABG-125I-LHRexo3 was incubated with a constant 
concentration of hCG and treated with UV for increasing time periods.  The extent of the 
labeling increased as the UV photolysis time increased, saturating at 90 s irradiation (Figure 3-
2,C).  The hormone subunits were not labeled when the sample was not irradiated with UV, 
indicating that the labeling required UV photolysis.  These results show that the labeling requires 
ABG-125I-LHRexo3, hCG and UV irradiation, and is saturable dependent on each of them.  Both 
of the hCG α and β subunits were labeled, slightly more α than β.  The extent of labeling of the 
α subunit and β subunit increased and saturated in parallel throughout the hCG, peptide, and UV 
dependent experiments (Figure 3-2,A-C).  These results suggest that the hCG subunits and 
photoprobe were stably and specifically arranged in the ternary complex.  In this spatial 
arrangement, the photoprobe is capable of labeling the αsubunit slightly better than the β 
subunit, suggesting new insights into the geometry and proximity of the interacting exoloop 3 
and the hCG subunits. 
 
3.  Specificity of Exoloop 3 Labeling 
Although the labeling was saturable, its specificity was unclear.  To test the biospecificity, ABG- 
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Figure 3-2.  Autoradiograph of photoaffinity labeled hCG subunits 
The peptide corresponding to the LHR exoloop 3 sequence (LHRexo3) was synthesized, 
derivatized with NHS-ABG and radioiodinated to produce ABG-125I-LHRexo3. 
(A) Increasing concentration of hCG were incubated with a constant concentration of ABG-125I-
LHRexo3 and irradiated with UV for 90 s.  (B) Increasing concentrations of ABG-125I-LHRexo3 
were incubated with a constant amount of hCG and irradiated with UV for 90 s.  (C) A constant 
concentration of ABG-125I-LHRexo3 was incubated with a constant amount of hCG and irradiated 
with UV for increasing time periods.  The samples were solubilized in SDS under the reducing 
condition and electrophoresed as described in "Materials and Methods".  After electrophoresis, 
the gels were dried and exposed under phosphoimager screen.  The intensity of each band in 
each lane was measured as described in "Materials and Methods".  The percentage of the labeled 
hCG α and β subunit bands in each lane were calculated based on the total intensity of a gel lane, 
and presented in the bar graph.
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125I-LHRexo3 was incubated with increasing concentrations of denatured hCG and irradiated with 
UV.  Denatured hCG was not labeled at (Figure 3-3).  To find out if higher concentrations of 
ABG-125I-LHRexo3 were needed for labeling denatured hCG, increasing concentrations of ABG-
125I-LHRexo3 were incubated with a constant amount of denatured hCG.  Higher concentrations of 
ABG-125I-LHRexo3 failed to label denatured hCG.  One concern is whether denatured hCG 
precipitated or adhered to the test tube during boiling in 8 M urea.  To test whether denatured 
hCG remains in solution, unlabeled hCG was mixed with radioactively labeled hCG in 8 M urea 
and boiled for 30 min.  Three microliter of the mixture was transferred to another tube every 3 
min, and the radioactivity was counted.  The transfer was quantitative, indicating that denatured 
hCG remained in solution and was present in photoaffinity labeling tubes (Figure 3-4).  The 
results demonstrate that the labeling requires bioactive hCG, not denatured hCG.  If the 
biospecificity is true, hCG and the exoloop 3 peptide should inhibit 125I-hCG binding to LHR, 
but denatured hCG should not.  To test the hypothesis, cells stably expressing wt LHR were 
incubated with 125I-hCG in the presence of increasing concentrations of nonradioactive hCG, 
nonradioactive LHRexo3 or denatured hCG (Figure 3-5).  The results show that both of the 
nonradioactive hCG and nonradioactive LHRexo3 inhibited 125I-hCG binding to LHR, but hCG 
was >10,000 times more potent than the peptide mimic.  However, denatured hCG failed to 
inhibit 125I-hCG binding to LHR.   
hCG and LH bind to the same receptor and induce similar hormone actions.  Therefore, 
LHRexo3 is expected to similarly label both hormones.  To test the possibility, increasing 
concentrations of LH and denatured LH were photoaffinity labeled with ABG-125I-LHRexo3 
(Figure 3-6).  Both of the α  and β subunits of LH were labeled, but denatured LH was not.   
Despite the biospecificity of photoaffinity labeling of hCG by LHRexo3, it was unclear whether 
the derivatization of the peptide with ABG impacted the peptide's specificity for hCG.  To test 
the possibility, hCG was photoaffinity labeled with ABG-125I-LHRexo3 in the presence of 
increasing concentrations of unlabeled LHRexo3 and scrambled LHRexo3.  The photoaffinity 
labeling was blocked by nonlabeled peptide but not by nonlabeled scrambled peptide (Figure 3-
7,A and B).  In addition, phospholipase A, phospholipase C, phospholipase D, and urokinase 
were incubated with ABG-125I-LHRexo3 and photolyzed.  These proteins were not photoaffinity 
labeled (Figure 3-7,C).  These results show the specificity of the hCG photoaffinity labeling.  
There is a remarkable difference in the photoaffinity labeling of hCG/LH and FSH  
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Figure 3-3. Photoaffinity labeling of denatured hCG   
(A) Increasing concentrations of denatured hCG were incubated with a constant amount of ABG-
125I-LHRexo3 and irradiated with UV for 90 s.  (B) Constant amounts of denatured hCG were 
incubated with increasing concentrations of ABG-125I-LHRexo3 and irradiated with UV for 90 s.  
The samples were processed as described in the legend of Figure 3-2. 
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Figure 3-4.  Fractionation of denatured hCG 
1 µg of 125I-hCG was denatured in 50 µl of 8 M Urea, 0.1 M DTT by boiling for 30 min.  3 µl of 
sample was collected every 3 min.  Radioactivity was measured for 1 min using a gamma 
counter. 
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Figure 3-5.   Inhibition of 125I-hCG binding to the receptor by LHRexo3 
125I-hCG was incubated with 293 intact cells expressing LHR in the presence of increasing 
concentrations of unlabeled LHRexo3 as described in "Materials and Methods".  The results were 
plotted against the concentration of unlabeled hCG, denatured hCG, and LHRexo3 peptide. 
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Figure 3-6.  Photoaffinity labeling of LH 
Increasing concentrations of human LH and denatured human LH were incubated with a constant 
amount of ABG-125I-LHRexo3 and irradiated with UV for 90 s.  The samples were processed as 
described in the legend of Figure 3-2. 
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Figure 3-7.  Specificity of photoaffinity labeling  
hCG was photoaffinity labeled with ABG-125I-LHRexo3 in the presence of increasing 
concentrations of nonlabeled LHRexo3 (A) and scrambled LHRexo3 (B).   (C) Various proteins 
(100 nM), hCG, phospholipase A (PLA), phospholipase C (PLC), phospholipase D (PLD) and 
urokinase (Uro) were incubated with ABG-125I-LHRexo3 and irradiated with UV for 90 s.  The 
samples were processed as described in the legend of Figure 3-2.
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with their respective exoloop 3 peptides.  Whereas both subunits of hCG and LH were labeled by 
ABG-125I-LHRexo3 (Figure 3-2, Figure 3-6), only the α subunit of FSH was labeled by ABG-125I-
FSHRexo3 (Figure 3-8,A) as previously described (113).  Since the α and β subunits of FSH 
comigrate in gel electrophoresis, photoaffinity labeled FSH was digested with PNGase F and 
electrophoresed, which resolves the two subunits.  The labeled band of FSH  corresponded to the 
α subunit, which is in contrast to the photoaffinity labeling of the FSH β subunit by the N-
terminal peptide of the FSHR exodomain (unpublished). 
Denatured FSH was not labeled at all (Figure 3-8, B and C).  The photoaffinity labeling 
of the FSH α subunit is remarkable because there are three potential residues, Lys580, Lys588 and 
Lys590, for ABG derivatization in FSHRexo3, as compared to two derivatization sites of Lys573 and 
Lys583 in LHRexo3.  The results suggest notable differences in the structure and interaction of the 
exoloop 3s of LHR and FSHR. 
 
4.  Relationship with Exoloops 1, 2, and Other Regions of Exodomain 
hCG binds the exodomain with high affinity and three regions have been identified for the 
interaction.  They are the N-terminal region (43, 110), Leu Rich Repeat 4 (111, 118), and the 
hinge region (112).  In addition, exoloop 2 is involved in the interaction of the exodomain and 
endodomain (72, 112).  The relationship between these various contact points likely plays a 
crucial role in the signal generation and the interaction of hCG and exoloop 3.  Therefore, it is 
necessary to determine the relationship among the various interactions.  hCG was photoaffinity 
labeled with 1 µM ABG-125I-LHRexo3 in the presence of 4 µM of nonlabeled exoloop peptides 
(LHRexo1, LHRexo2 and LHRexo3), N-terminal peptide (LHR18-36), Leu Rich Repeat 4 peptide 
(LHR96-115), and hinge region peptide (LHR246-269).  Nonlabeled LHRexo3, LHR96-115, and LHR246-
269 blocked the labeling (Figure 3-9).  LHRexo1and LHRexo2 inhibited the labeling, but the 
inhibition by LHRexo1 was considerably weak.  These results suggest diverse affinities of the 
hCG labeling with these LHR peptides.  On the other hand, LHR18-36 failed to inhibit the 
labeling.  These results suggest the specificity of the hCG labeling by ABG-125I-LHRexo3, which 
necessitates further studies. 
 
C.  Discussion 
Our results show that LHRexo3 specifically photoaffinity labeled both subunits of hCG/LH,  
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Figure 3-8.   Photoaffinity labeling of FSH 
(A) Human FSH was photoaffinity labeled with increasing concentrations of ABG-125I-FSH, 
treated with PNGase F, and processed as described in "Materials and Methods".  In addition, 125I-
FSH was electrophoresed with and without digestion with PNGase F.  (B) A constant amount of 
denatured FSH was photoaffinity labeled with increasing concentrations of ABG-125I-FSHRexo3.  
(C) Increasing concentrations of denatured FSH were photoaffinity labeled with a constant 
amount of ABG-125I-FSHRexo3.  The samples were processed as described in the legend of Figure 
3-2. 
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Figure 3-9. Effects of other LHR peptides on photoaffinity labeling of hCG     
hCG was photoaffinity labeled with ABG-125I-LHRexo3 in the presence of 4 µM of nonlabeled 
peptides: exoloop 1 peptide (Exo1), exoloop 2 peptide (Exo2), exoloop 3 peptide (Exo3), 
scrambled exoloop 3 peptide (Exo3S), LHR18-36 (18-36), LHR96-115 (96-115), and LHR246-269 
(246-269). 
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whereas the labeling of FSH by FHRexo3 was restricted to the αsubunit of FSH.  These 
gonadotropins share the common α subunits as well as the common hormone signals to activate 
AC for cAMP production and PLC β for production of IP and diacyl glycerol production (6, 
121).  Because of these common structural features and functions, the common α subunit has 
been suspected to be involved in the hormone action.  Our results clearly support the possibility.  
In addition, they provide intriguing new insights into a pivotal question of how hCG/LH and 
FSH distinctly generate the common hormone action.  The differential photoaffinity labeling of 
hCG/LH and FSH provides an explanation.  Both subunits of hCG/LH are in the proximity of the 
C-terminal region of LHR exoloop 3, whereas the α subunit of FSH is close to the FSHR 
exoloop 3.  The crystal structures of hCG (53, 104) and FSH (8) support these distinct 
interactions between the hormones and three exoloops.  Although the overall structures are 
similar, there are differences in the β subunits that may be important with respect to receptor 
binding specificity or signal generation (8). 
Though our previous studies (125) suggest the involvement of exoloop 3 in hormone 
binding, it was unclear whether exoloop 3 interacts with hCG.  The specific photoaffinity 
labeling of hCG by ABG-125I-LHRexo3 and the inhibition of hCG binding to LHR by the peptide 
indicates the direct interaction of exoloop 3 and hCG.  The photoaffinity labeling is blocked by 
the exoloop 2 peptide, the LRR 4 peptide (LHR96-115), and the hinge region peptide (LHR246-269).  
The simplest explanation is that the competing peptides bind hCG at the same or overlapping 
sites.  Alternatively, allosteric effects or their putative interactions with ABG-125I-LHRexo3 might 
have disrupted the photoaffinity labeling.  One way to address this issue is to photoaffinity label 
hCG with the competing receptor peptides.  Both of the LRR 4 peptide  
(111) and hinge peptide (112) photoaffinity label hCG, indicating their direct interactions with 
hCG.  Therefore, the exoloop 3 peptide, LRR 4 peptide, and hinge peptide either interact with 
hCG at the same or overlapping sites or bind at distinct sites in hCG but allosterically impact 
another's binding to hCG.  Consistent with the latter possibility is the fact that hCG undergoes a 
conformational change upon the initial binding with the receptor (130).  Whether the exoloop 2 
peptide interacts with hCG is unclear.  In contrast, the exoloop 1 peptide and the N-terminal 
peptide (LHR18-36) were less potent in the inhibition of photoaffinity labeling of hCG by ABG-
125I-LHRexo3.  Apparently, the labeling site of the exoloop 3 peptide in hCG is different from the 
N-terminal peptide labeling site.  The endodomain is the site of signal generation, which likely 
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involves all three exoloops.  It will be of interest to see whether the differential signal 
generations for PLC β/IP induction and AC/cAMP induction are related with the distinct potency 
of the exoloops 1 and 2 to inhibit the labeling of hCG by the exoloop 3 peptide.  Our data show 
that exoloop 3 plays roles in the activation of PLC β/IP induction and activation of AC/cAMP 
induction, as well as in the affinity of hormone binding.  However, these roles are not equally 
important: the PLCβ activation is most crucial and hormone binding is least crucial.  In fact, the 
role in the PLCβ activation is so crucial that most of the exoloop 3 residues appear to be 
involved.  In contrast, there are fewer residues that appear crucial for the AC activation.  They 
are Pro575, Leu576, Val579 and Lys583.  Substitution of these residues with Ala impaired the 
activation of PLCβ, AC, or both.  In addition, exoloop 3 constrains hormone binding at the 
exodomain, and Ala substitution for the residues often improved the binding affinity.  In 
particular, the Lys583Ala substitution resulted in a 2 fold improvement in the binding affinity.   
These residues are not in tandem in a linear sequence, suggesting a spatial orientation or 
cluster.  The expression level of the LHR mutants varied from 2,000-230,000 receptors/cell.  
However, it does not appear to hold in the gonadotropin receptors, at least in the homologous 
receptor system.  Over the years, different individuals in our laboratory have consistently shown 
that varying numbers of wild type receptors in the range of 8,000 - 265,000 receptors/cell 
induced the similar maximum cAMP production as long as the same HEK 293 cell line was 
used.  In addition, the Pro574Ala mutant induced consistently the lowest maximum cAMP level, 
which is 19% of the wild type value with 2,400 receptors/cell in this study and 24% with 17,000 
receptors/cell in the previous study (109).  This result is consistent with the classic observations 
(131-133); only a small fraction of receptors expressed on the cell surface are actually involved 
in receptor activation, whereas the bulk of receptors are involved in taking up excess hormones 
for internalization and degradation.  In conclusion, we present the first evidence that LHR 
exoloop 3 interacts with hCG and is involved in the differential activation of PLC β and AC.   
Although FSHR exoloop 3 interacts with FSH and differentially modulates activation of 
PLC β and AC, there are striking differences in the mode of the interactions and modulation 
between the two systems.  LHR exoloop 3 is close to both of the hCG α and β subunits, whereas 
FSHR exoloop 3 is close to the FSH α subunit.  In parallel to these distinct spatial arrangements, 
the tandem Leu-Ile sequence near the middle of exoloop3 is crucial for AC activation in FSHR 
but not in LHR.  The penultimate C-terminal residue is essential for PLC β activation in LHR but 
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not in FSHR.  The interaction of exoloop 3 with hCG is related to the interactions of hCG with 
the hinge and LRR4 regions but not the N-terminal region of the exodomain.  Our results provide 
new insights into the transition from the initial interaction of hCG with the exodomain to the 
subsequent interaction with the exoloops, leading to signal generation.  
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Appendices 
 
Abbreviation 
AC   Adenylyl cyclase  
cAMP  3',5-cyclic adinosine monophosphate 
DMSO  Dimethyl sulfoxide 
DTT  Dithiothreitol 
FSH   Follicle stimulating hormone  
GPCR  G-protein coupling receptor 
hCG  Human Chorionic Gonadotropin 
IC50  Effective concentration for 50% inhibition 
IP   Inositol phosphate 
IP1   Inositol monophosphate 
IP2   Inositol bisphosphate  
IP3   Inositol trisphosphate  
IPt   Total inositol phosphate 
LH  Luteinizing hormone 
LHR  LH/CG receptor 
LRR  Leucine-Rich Repeat 
NHS-AB N-hydroxysulfosuccinimide ester of 4-azidobenzic acid 
NHS-ABG N-hydroxysulfosuccinimide ester of 4-azidobenzoyl glycine 
NP-40  Nonidet P-40 
PBS  Phosphate buffered saline  
PLC   phospholipase C 
SDS-PAGE Sodium Dodecyl Sulfate – PolyAcrylamide Gel Electrophoresis 
SES   Ethylene glycolbis-[sulfosuccinimidylsuccinate] 
TM  Transmembrane domain 
TSH   Thyroid stimulating hormone 
UV  Ultraviolet 
WT  Wild Type  
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